The FDA has accepted the application for belzutifan for advanced, unresectable, or metastatic pheochromocytoma and paraganglioma.

The FDA has extended the review period for the New Drug Application for elamipretide for the treatment of Barth syndrome.

The FDA granted priority review for belzutifan for treating advanced pheochromocytoma and paraganglioma, with a PDUFA date ...

The US Food and Drug Administration (FDA) will soon decide on whether to expand the label of MSD’s Welireg (belzutifan) to ...

Merck MRK announced that the FDA has accepted its supplemental new drug application (sNDA) seeking approval of its oral ...

The life insurance medical exam is part of many insurers’ underwriting processes to evaluate the risk of insuring you. The ...

Unable to innovate or even buy basic materials, and struggling to keep staff while operating antiquated systems, prison ...

The creation of thousands of new prison spaces in England and Wales has been held up by environmental regulations, as capacity continues to be squeezed behind bars.

The Food and Drug Administration on Tuesday approved Ozempic to reduce the risk of serious complications in people who have ...

Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the ...

Scientists have unveiled a groundbreaking method to test how thousands of active substances influence cellular metabolism ...

Lab-developed tests (LDTs) are laboratory tests where blood is drawn and placed in a test tube to help with identification, ...